Objective: To evaluate long-term treatment efficacy and safety of one-time telemedicine consultations for nonacute headaches.
was that telemedicine consultations are noninferior to traditional consultations in treatment and safety at 12 months.
METHODS Trial design. We conducted this noninferiority trial at the department of Neurology in Tromsø University Hospital in Norway (figure e-1).
Power was calculated on the assumption of a normal distribution of a primary binary satisfaction variable with an inferiority limit of 15%. With an a of 0.01 in a 98% confidence interval (CI), 127 participants in each group were required to reach a power of 95%.
In the area of coverage, access to all patient records in Northern Norway is made possible by a shared database in the Distributed Information and Patient System for hospitals (DIPS ASA, Bodø, Norway). 4 From September 30, 2012, until March 30, 2015, we consecutively screened and recruited 402 (to ensure applicable 12-month data) out of 557 headache patients (figure 1). We included Norwegian-speaking female and male participants aged 16-65 years referred from primary care to a neurologist for headache management with a maximum 4 months waiting time from date of referral. Patients who underwent a neurologic headache consultation within the last 2 years were excluded. We defined headache as nonacute, and less likely secondary, if it started gradually, occurred at least 4 weeks prior to referral, and showed no clinical or radiologic abnormalities. 5, 6 Findings from the clinical neurologic examination and neuroimaging performed as part of the Figure 1 Flow of participants through the study
ITT 5 intention-to-treat.
primary clinical evaluation were regarded as sufficient supplementary information to perform a realistic safety investigation. All participants received written study information and filled out social and demographic questionnaires, Headache Impact Test-6 (HIT-6), 7 visual analogue pain scale (VAS), 8 and consent forms beforehand. At entrance, all participants came to the hospital in Tromsø and met at the patient reception in the neurologic department (figure e-1). A nurse controlled the patient's selfadministered forms and the consent, and phoned the external research department at the University Hospital for block randomization. Randomization was computer-generated by using an Rnd function in Microsoft (Redmond, WA) Access. Then, the nurse followed each participant either to a patient examination room at the department (traditional group) or to a videoconference room located next to the Department of Neurology (telemedicine group).
Patients in the traditional group were consulted in-person, face-to-face in the examination room at the Department of Neurology. The neurologists conducted telemedicine visits via a Cisco (Moorestown, NJ) EX60 unit from the examination rooms where the traditional consultations took place. The patient was then located remotely in the videoconference room. The videoconference room had a Cisco C40 integrator package installed 9 providing a 2-way video and audio communication between the neurologist and the patient. The neurologists (K.I.M. and S.I.B.) checked the inclusion criteria, filled in the diagnostic checklist, performed a standardized interview without neurologic examinations, and completed the consultation.
Both the telemedicine and the traditional in-person consultation was a one-time consultation of new referred headache patients. In most cases, only the neurologist and the patient were present at consultation, but a relative or a friend accompanied a few.
Questionnaires and patient records. We sent a structured questionnaire by patient preference, either through an online survey service (Questback) or by mail at 3 and 12 months with a reminder after 2 weeks to the nonresponders. 10 Participants were asked the following:
1. To complete the HIT-6 7 2. For the intensity of headache measured on VAS 8 3. To fill in number of headache days and headache attacks per month for the last 3 months 4. For the subjective change in headache frequency and intensity:
"Is the headache better, unchanged, or worse?" "Is the headache frequency reduced, unchanged, or increased?" "Is the headache intensity reduced, unchanged, or increased?" 5. For other disability measures, including employment, sick leave, and other social benefits 6. For the use of medication, including frequency of painkillers and triptans 7. Whether patients underwent brain neuroimaging with CT, MRI, or both within 12 months after consultation 8. For recall of the given headache diagnosis, compliance with given treatment, and number of general practitioner visits within the 12 months after the baseline consultation 9. For number of neurologic visits and hospitalizations for headaches within the 12 months after the baseline consultation
Outcome variables. Demographics were compared between telemedicine and traditional groups of all participants and those answering the 12-month questionnaire ( HIT-6, and VAS of all the participants and those answering the 12-month questionnaire were recorded (table 1) . Efficacy endpoints and general practitioner follow-up visits were evaluated through the questionnaires. Safety endpoints, neurologic follow-ups, and hospitalizations were reported by the participants in the 12-month questionnaire, but also validated by screening the patients' hospital records from the year passed since the baseline consultation.
The primary efficacy endpoint was a change in headache burden measured by HIT-6 across 3 periods (at consultation, at 3 months, and at 12 months). The HIT-6 is a patient-reported headache outcome measure that assesses the influence of headache on daily life. It consists of 6 headache questions relating to daily activities and work, pain, fatigue, and irritability. Every question has 5 answers (never, rarely, sometimes, very often, and always), and each answer scores 6, 8, 10, 11, or 13 points, respectively. A score above 56 has substantial influence on daily life.
The primary safety outcome was incidents of secondary headaches revealed within 12 months after the headache specialist consultation.
The main secondary efficacy endpoint was a change in headache intensity measured on VAS across 3 periods (at consultation, at 3 months, and at 12 months). The horizontal VAS scale from 0 to 10, 0 5 no pain, 10 5 worst possible pain, is valid and reliable for assessing headache intensity and many other pain conditions. 8 Other secondary efficacy outcome measures were change in work status, sick leave, perception of headache, headache days per month over the last 3 months, frequency of painkillers, triptans, and headache prophylactics in the last month, and diagnostic recall at 12 months. The use of painkillers and triptans were divided into 4 groups: .3 days a week, 1-2 days a week, ,1 day a week but . every second week, and ,1 day every second week.
Secondary safety outcomes were assessed by findings of pathology on brain neuroimaging requisitioned at the specialist consultation. The frequency of headache-related hospitalizations and specialist headache visits within 12 months after the specialist consultation were assessed to evaluate the quality and safety of telemedicine. 12 Other secondary safety outcomes were compliance with treatment and abnormal CSF analysis demonstrated within 12 months after the specialist headache consultation.
Participants were brain scanned in CT or in 1.5T MRI machines. The CT was performed by a spiral technique with reconstructions in 3 planes (coronal, sagittal, and axial). All MRIs had a Head/SENSE-Head/Flex-L coil and included at least the following sequences: sagittal 3D fluid-attenuated inversion recovery (FLAIR), axial T2 turbo spin echo 4 mm, axial T2 fast field echo 4 mm, axial diffusion 4 mm, and sagittal T1 spin echo 5.5 mm. All neuroimages were evaluated either by experienced radiologists or with a second opinion from neuroradiologists.
Neuroimaging findings were classified as being normal, nonsignificant, or significant. 13, 14 Normal was defined as no abnormalities or white matter hyperintensities (T2/FLAIR) corresponding to #1 on the Fazekas scale, nonsignificant as abnormalities not influencing further management or Fazekas scale .1, and significant if abnormalities needed follow-up treatment or were categorized as clinically significant neurologic findings according to given criteria. 13, 15 Statistical methods. Data were analyzed with SPSS (Armonk, NY) 23. To ascertain normality, we inspected continuous variables by histogram and calculated kurtosis and skewness before performing independent-samples t tests. Categorical variables were compared using x 2 test and presented as numbers and percentages. All tests were 2-sided. Statistical significance was set at p , 0.05. Intention-to-treat analysis was performed by using last observed value carrying forward for continuous variables together with cross-tabulation with missing values for categorical variables.
Variables not prespecified are labeled in Results. We used mixed between-within participants analysis of variance (ANOVA) to assess whether change in HIT-6 and VAS differed between telemedicine and traditional consultations across 3 time periods. These results were presented as Wilks l, partial h 2 , and F score. Absolute results and numbers needed to treat/harm were calculated for the primary and main secondary outcome measures.
Consent, registration, and ethical approval. We received oral and written consent from all participants before data collection. The Norwegian National Committee for Medical and Health Research Ethics approved the study (2009/1430/REK), and it conforms with the Helsinki Declaration. 16 The trial was registered at the Norwegian Research and Management database (FAS ID3897/HST959-10) and retrospectively at ClinicalTrials.gov (NCT02270177). 17 RESULTS The 3-month questionnaire was answered by 348/402 (86.6%), and 291/402 (72.4%) answered the 12-month questionnaire. HIT-6 Cronbach a coefficients were 0.84, 0.89, and 0.90 at baseline and 3 and 12 months, respectively. Feasibility outcomes, 3-month followup data, and recommended interventions are published elsewhere. 9, 18 Mixed between-within participants ANOVA with a significance level of 0.05 and 95% CIs showed no differences in HIT-6 or VAS between the telemedicine and the traditional group over 3 periods: Figure 2 compares the decline in HIT-6 and VAS Table 1 Baseline demographics and clinical characteristics of the randomized groups in patients referred to a specialist for headache scores between telemedicine and traditional consultations across 3 periods. Table 2 compares treatment efficiency variables between telemedicine and traditional headache consultations of patients who answered the 12-month questionnaire. Table 3 compares quality and safety variables between the 2 groups within 12 months after the consultation.
We identified one secondary headache in each group (table 3 Prespecified Headache Impact Test-6 (HIT-6) and visual analogue scale (VAS) from baseline to 12 months after consultation (A) HIT-6 (p 5 0.84) and (B) VAS (p 5 0.64) from baseline to 12 months after consultation. The significant neuroimaging findings in the telemedicine group included a middle cerebral artery aneurysm (1 patient), vasospasms (1 patient), white matter damage of suspected prenatal origin (2 patients), 1 ArnoldChiari malformation type 1, and 1 benign tumor in the masseter muscle. In the traditional group, 2 patients had meningioma, and 1 had a Dandy-Walker anomaly. None of the above-mentioned findings was associated with the headaches diagnosed at the consultation.
All 19 lumbar punctures, except in the patient with idiopathic intracranial hypertension, had normal CSF opening pressure, and all had normal leucocyte, protein, and isoelectric focusing.
DISCUSSION With similar conditions in telemedicine and traditional headache consultations of new patients recruited consecutively from our neurologic outpatient department, we found no significant differences in long-term treatment efficacy measured repeatedly with HIT-6 and VAS over 12 months. By thoroughly rereading every participant's hospital patient records, 1 secondary headache was identified in each group within the first year after the headache consultation, and findings on neuroimaging were equally distributed between the 2 randomized groups. Further evaluation after 1 year showed that headache patients consulted through telemedicine were followed up in a similar manner as those who underwent traditional consultations. With no significant differences between the 2 methods of consultation, telemedicine is as efficient and safe as traditional visits in long-term treatment outcome of nonacute headaches.
There are a few randomized controlled 2-way visual and audio telemedicine trials of neurologic conditions beyond stroke. [19] [20] [21] Other randomized studies are based on treatment of already diagnosed conditions. [22] [23] [24] Still, telemedicine is widely used in neurologic departments as well as for headache management. 12, 25, 26 Our study shows that after 12 months of follow-up, headache burden, subjective and objective headache change, or treatment follow-up Table 3 Safety of specialist telemedicine consultations for nonacute headaches outcomes are not statistically in favor of traditional visits ( figure 2 and table 2 ). The long-term similar outcomes of both groups adds to the cost-saving analysis in our previous article. 9 In a cost-minimization perspective, we now evaluate these results as strongly indicating cost-effectiveness for telemedicine. 9 This randomized trial will help to build a base of evidence for telemedicine consultations for nonacute headaches, and prevent making it less safe than it has to be.
The list of differential diagnoses of headaches is one of the longest in medicine, but fortunately, secondary headaches caused by structural brain disorders are rare. 27 However, some secondary headaches may be life-threatening, and physicians often struggle to see the forest for the trees. 6 Some neurologists in Norway require MRI before a patient with nonacute headache is referred, and this is also the case in the United States. 28 During a headache consultation, physicians should aim at identifying warning signs for secondary causes of headache. 6 By excluding secondary headaches from the referrals as performed in clinical practice, the risk of missing secondary headaches due to misdiagnosis was small. After 12 months, the frequency of secondary headaches, brain neuroimaging pathology, hospital stays due to misdiagnoses or headache-related treatment, as well as compliance and lumbar puncture results were comparable between the groups. Although we applied the same classification criteria as a population-based study, there were less significant findings on the brain imagings. 13 One reason may be that we initially excluded secondary headaches, but patients in our study were also younger. The present study documents that telemedicine evaluation of nonacute headaches without performing clinical neurologic examination can be considered safe. Conversely, in some geographic areas, pathologic findings on brain CT in patients with nonacute headaches are reported almost as high as in 50%, and possibly rendering telemedicine less safe. 29 Generalizability and low risk of selection bias are strengths of this study since we consecutively recruited and consulted referred patients to a daily neurologic outpatient department. The distances to other neurologic departments and private practicing neurologists are extensive and located outside the range of the hospital's territory. Subsequently, the risk of loss to follow-up is negligible. Randomization, high response rate on the questionnaires, and thorough review of every participant's patient records are other strengths that ensure high inclusion rates and few issues with attrition.
Although we consulted all patients inside the hospital, providing similar group settings, the study design makes the study conditions less realistic. Holding the telemedicine visits within the same hospital as traditional visits clearly cuts both ways. Removing potential confounding effects of travel, location, and the use of different health care personnel strengthens the internal validity, but may also give a false feeling of security from a hospital environment in the telemedicine group. This, and the fact that the patients had to make a journey, may bring value to and build up patients' preference and satisfaction of a remote experience. Despite potential detraction from this, patients were highly satisfied in both groups, and the frequency of satisfied patients in the telemedicine group was noninferior to the traditional group. 18 Lack of a placebo group and blinding are other weaknesses, but would be difficult to implement.
Although the efficacy and safety of telemedicine are comparable to traditional headache visits, the decline in HIT-6 and VAS in both groups could be caused by a deviation to the mean. 30 In line with this reasoning, the efficacy of either consultation type to usual headache care has not been demonstrated. On the other hand, the results are in range of a minimal clinically important difference for HIT-6 and beyond that of VAS. [31] [32] [33] Another uncertainty is that our analyses of neuroimaging were based on radiologic descriptions from clinical practice, comprised of both CT and MRI, and did not differentiate between them. On the other hand, this reflects a real-life context in a neurologic outpatient department.
Technologies such as telemedicine are not considered neutral, but may have profound influence on history and society, and are in various degrees exposed to interpretations by users. 34 The positive aspects in this study make telemedicine a compensation for the lack of headache specialists in our area. However, rules and regulations may hinder use of new technology. 35, 36 The fact that headaches often are underdiagnosed and suboptimally treated in general practice encourages use of telemedicine to countervail these circumstances. 37 In addition to the positive long-term efficacy and safety results in this study, we have previously shown that telemedicine is an acceptable, satisfying, and feasible consultation form for nonacute headaches. 9, 18 Still, up to 75% of new information and communication technologies turn out to fail. 38 To become successful, many examples show that such technologies ought to be built through a bottom-up procedure rather than a top-down approach. 39, 40 Because the foundation of our study is not built from scratch, but through a bottom-up procedure, using consulting methods and equipment already incorporated in our hospital, the chance of it becoming successfully incorporated in clinical practice is high.
Telemedicine consultation for nonacute headache is noninferior to traditional in-person clinic evaluation in respect to long-term treatment efficacy and safety, and should be a good alternative for patients presenting with nonacute headache. This study provides Class III evidence that a one-time telemedicine consultation for patients with nonacute headache is noninferior to a one-time traditional consultation regarding long-term treatment outcome and safety.
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